Ischemic Heart Disease (IHD)Drugs Market Report

Global and Region Ischemic Heart Disease (IHD)Drugs Market Demand & Opportunity Outlook 2022-2028

  • POSTDATE：Aug 03, 2022
  • PAGES：226
  • REPORT CODE：GMM1014120
  • REPORT SUMMARY
  • TABLE OF CONTENTS

  • Ischemic heart disease (IHD), refers to a group of diseases which includes stable angina, unstable angina, myocardial infarction, and sudden cardiac death. It is within the group of cardiovascular diseases of which it is the most common type. A common symptom is chest pain or discomfort which may travel into the shoulder, arm, back, neck, or jaw.

    Ways to reduce CAD risk include eating a healthy diet, regularly exercising, maintaining a healthy weight, and not smoking. Medications for diabetes, high cholesterol, or high blood pressure are sometimes used. Additional medications such as antiplatelets, beta blockers, or nitroglycerin may be recommended.

    The report details the trend, potential and market size of Ischemic Heart Disease (IHD)Drugs market, and analyzes the current situation and prospects of the market from both qualitative and quantitative aspects, which can be roughly divided into three parts.

    The first part (Chapter1-7) mainly covers the qualitative analysis of Ischemic Heart Disease (IHD)Drugsmarket, defines the market attractiveness level of Ischemic Heart Disease (IHD)Drugs market through Porter's Five Forces Analysis, and summarizes the different factors in the overall environment through PEST analysis. Understand the distribution of industrial chain value in each link of industrial chain through the analysis of industrial chain structure. Thus estimate the market space of each link.

    The second part (Chapter8-12), based on the segmentation of Ischemic Heart Disease (IHD)Drugs industry, describes the types of Ischemic Heart Disease (IHD)Drugs market, the applications of major players and the market size, and deeply analyzes the current situation of the global Ischemic Heart Disease (IHD)Drugs market and the development prospects and opportunities of Ischemic Heart Disease (IHD)Drugs industry.

    The third part (Chapter14-15) includes the market positions of the major players and information on the market participants, which will help you gain a comprehensive understanding of the current competitive situation and potential growth opportunities in the market.

    As COVID-19 continues to impact the global economy in 2022, the report also considers the short - and long-term impacts of COVID-19 on the global Ischemic Heart Disease (IHD)Drugs market in Chapter 13.

    By Player:

    • AstraZeneca

    • Sanofi

    • Novartis

    • Bayer

    • Eli Lilly

    • Pfizer

    By Type:

    • Anti-dyslipidemic Drugs

    • Calcium Channel Blockers

    • Beta-blockers

    • ACE Inhibitors

    • ARBs

    • Vasodilators

    • Antithrombotic Agents

    By End-User:

    • Stable Angina

    • Unstable Angina

    • Prinzmetal's Angina

    • STEMI

    • NSTEMI

    By Geography:

    • United States

    • Europe

    • China

    • Japan

    • India

    • South Korea

  • TABLE OF CONTENT

    1 Introduction

    • 1.1 Market Definition

    • 1.2 Market Segment Analysis

    • 1.3 Market Size 2022

    • 1.4 Ischemic Heart Disease (IHD)Drugs Market Outlook: Forecast for 2022 - 2028

    • 1.5 Pricing Analysis

    2 Executive Summary

    3 Ischemic Heart Disease (IHD)Drugs Market Lineage Outlook

    • 3.1 Parent Market Outlook

    • 3.2 Related/Ancillary Market Outlook

    • 3.3 Penetration & Growth Prospect Mapping, 2022

    4 Market Analysis Tools: Porter's Five Forces

    • 4.1 Supplier Power

    • 4.2 Buyer Power

    • 4.3 Substitution Threat

    • 4.4 Threat of New Entrants

    • 4.5 Competitive Rivalry

    5 Ischemic Heart Disease (IHD)Drugs Industry Analysis - PEST (Political & Legal, Economic, Social, and Technological)

    • 5.1 Political/Legal Landscape

    • 5.2 Economic Landscape

    • 5.3 Social Landscape

    • 5.4 Technology Landscape

    6 Ischemic Heart Disease (IHD)Drugs Market - Value Chain Analysis

    • 6.1 Industry's Value Chain Analysis

    • 6.2 Product Life Cycle

    • 6.3 User Perspective Analysis

    7 Region and Country-wise Ischemic Heart Disease (IHD)Drugs Market Analysis and Outlook to 2022

    • 7.1 Global Ischemic Heart Disease (IHD)Drugs Consumption (2017-2022)

    • 7.2 United States Ischemic Heart Disease (IHD)Drugs Consumption (2017-2022)

    • 7.3 Europe Ischemic Heart Disease (IHD)Drugs Consumption (2017-2022)

    • 7.4 China Ischemic Heart Disease (IHD)Drugs Consumption (2017-2022)

    • 7.5 Japan Ischemic Heart Disease (IHD)Drugs Consumption (2017-2022)

    • 7.6 India Ischemic Heart Disease (IHD)Drugs Consumption (2017-2022)

    • 7.7 South Korea Ischemic Heart Disease (IHD)Drugs Consumption (2017-2022)

    8 Region and Country-wise Ischemic Heart Disease (IHD)Drugs Market Analysis and Outlook to 2028

    • 8.1 Global Ischemic Heart Disease (IHD)Drugs Consumption Forecast (2022-2028)

    • 8.2 United States Ischemic Heart Disease (IHD)Drugs Consumption Forecast (2022-2028)

    • 8.3 Europe Ischemic Heart Disease (IHD)Drugs Consumption Forecast (2022-2028)

    • 8.4 China Ischemic Heart Disease (IHD)Drugs Consumption Forecast (2022-2028)

    • 8.5 Japan Ischemic Heart Disease (IHD)Drugs Consumption Forecast (2022-2028)

    • 8.6 India Ischemic Heart Disease (IHD)Drugs Consumption Forecast (2022-2028)

    • 8.7 South Korea Ischemic Heart Disease (IHD)Drugs Consumption Forecast (2022-2028)

    9 Global Ischemic Heart Disease (IHD)Drugs Market Outlook by Types and Applications to 2022

    • 9.1 Global Ischemic Heart Disease (IHD)Drugs Consumption and Growth Rate by Type (2017-2022)

      • 9.1.1 Global Anti-dyslipidemic Drugs Consumption and Growth Rate (2017-2022)

      • 9.1.2 Global Calcium Channel Blockers Consumption and Growth Rate (2017-2022)

      • 9.1.3 Global Beta-blockers Consumption and Growth Rate (2017-2022)

      • 9.1.4 Global ACE Inhibitors Consumption and Growth Rate (2017-2022)

      • 9.1.5 Global ARBs Consumption and Growth Rate (2017-2022)

      • 9.1.6 Global Vasodilators Consumption and Growth Rate (2017-2022)

      • 9.1.7 Global Antithrombotic Agents Consumption and Growth Rate (2017-2022)

    • 9.2 Global Ischemic Heart Disease (IHD)Drugs Consumption and Growth Rate by Application (2017-2022)

      • 9.2.1 Global Stable Angina Consumption and Growth Rate (2017-2022)

      • 9.2.2 Global Unstable Angina Consumption and Growth Rate (2017-2022)

      • 9.2.3 Global Prinzmetal's Angina Consumption and Growth Rate (2017-2022)

      • 9.2.4 Global STEMI Consumption and Growth Rate (2017-2022)

      • 9.2.5 Global NSTEMI Consumption and Growth Rate (2017-2022)

    10 Global Ischemic Heart Disease (IHD)Drugs Market Outlook by Types and Applications to 2028

    • 10.1 Global Ischemic Heart Disease (IHD)Drugs Consumption Forecast and Growth Rate by Type (2022-2028)

      • 10.1.1 Global Anti-dyslipidemic Drugs Consumption Forecast and Growth Rate (2022-2028)

      • 10.1.2 Global Calcium Channel Blockers Consumption Forecast and Growth Rate (2022-2028)

      • 10.1.3 Global Beta-blockers Consumption Forecast and Growth Rate (2022-2028)

      • 10.1.4 Global ACE Inhibitors Consumption Forecast and Growth Rate (2022-2028)

      • 10.1.5 Global ARBs Consumption Forecast and Growth Rate (2022-2028)

      • 10.1.6 Global Vasodilators Consumption Forecast and Growth Rate (2022-2028)

      • 10.1.7 Global Antithrombotic Agents Consumption Forecast and Growth Rate (2022-2028)

    • 10.2 Global Ischemic Heart Disease (IHD)Drugs Consumption Forecast and Growth Rate by Application (2022-2028)

      • 10.2.1 Global Stable Angina Consumption Forecast and Growth Rate (2022-2028)

      • 10.2.2 Global Unstable Angina Consumption Forecast and Growth Rate (2022-2028)

      • 10.2.3 Global Prinzmetal's Angina Consumption Forecast and Growth Rate (2022-2028)

      • 10.2.4 Global STEMI Consumption Forecast and Growth Rate (2022-2028)

      • 10.2.5 Global NSTEMI Consumption Forecast and Growth Rate (2022-2028)

    11 Global Ischemic Heart Disease (IHD)Drugs Import and Export Analysis (Top 5 Countries)

    • 11.1 Global Ischemic Heart Disease (IHD)Drugs Import by Region (Top 5 Countries) (2017-2028)

    • 11.2 Global Ischemic Heart Disease (IHD)Drugs Export by Region (Top 5 Countries) (2017-2028)

    12 Coronavirus Disease (COVID-19) Impact

    • 12.1 Industry Impact Analysis

    • 12.2 Ischemic Heart Disease (IHD)Drugs Market Outlook to 2028 - COVID-19 Affected Forecasts

    13 Competition Matrix

    • 13.1 Target Markets

    • 13.2 Comprehensive Analysis of Products in Competitive Markets

    14 Global Ischemic Heart Disease (IHD)Drugs Market Competitive Analysis

    • 14.1 AstraZeneca

      • 14.1.1 AstraZeneca Company Details

      • 14.1.2 AstraZeneca Ischemic Heart Disease (IHD)Drugs Sales, Price, Value and Gross Profit (2017-2022)

      • 14.1.3 AstraZeneca Ischemic Heart Disease (IHD)Drugs Product and Service

    • 14.2 Sanofi

      • 14.2.1 Sanofi Company Details

      • 14.2.2 Sanofi Ischemic Heart Disease (IHD)Drugs Sales, Price, Value and Gross Profit (2017-2022)

      • 14.2.3 Sanofi Ischemic Heart Disease (IHD)Drugs Product and Service

    • 14.3 Novartis

      • 14.3.1 Novartis Company Details

      • 14.3.2 Novartis Ischemic Heart Disease (IHD)Drugs Sales, Price, Value and Gross Profit (2017-2022)

      • 14.3.3 Novartis Ischemic Heart Disease (IHD)Drugs Product and Service

    • 14.4 Bayer

      • 14.4.1 Bayer Company Details

      • 14.4.2 Bayer Ischemic Heart Disease (IHD)Drugs Sales, Price, Value and Gross Profit (2017-2022)

      • 14.4.3 Bayer Ischemic Heart Disease (IHD)Drugs Product and Service

    • 14.5 Eli Lilly

      • 14.5.1 Eli Lilly Company Details

      • 14.5.2 Eli Lilly Ischemic Heart Disease (IHD)Drugs Sales, Price, Value and Gross Profit (2017-2022)

      • 14.5.3 Eli Lilly Ischemic Heart Disease (IHD)Drugs Product and Service

    • 14.6 Pfizer

      • 14.6.1 Pfizer Company Details

      • 14.6.2 Pfizer Ischemic Heart Disease (IHD)Drugs Sales, Price, Value and Gross Profit (2017-2022)

      • 14.6.3 Pfizer Ischemic Heart Disease (IHD)Drugs Product and Service

    15 Appendix


    TABLE OF CHARTS

    • Table Definition of Ischemic Heart Disease (IHD)Drugs

    • Figure Ischemic Heart Disease (IHD)Drugs Picture

    • Table Global Ischemic Heart Disease (IHD)Drugs Market Size and Forecast 2022 - 2028 (USD million)

    • Figure Global Ischemic Heart Disease (IHD)Drugs Market Size and Forecast 2022 - 2028 (USD million)

    • Figure Global Ischemic Heart Disease (IHD)Drugs Market: Year-over-year Growth 2022 - 2028 (%)

    • Table Parent Market Analysis

    • Figure Parent Market Price

    • Table Related/Ancillary Market Outlook Analysis

    • Table Supplier Power Analysis

    • Table Buyer Power Analysis

    • Table Substitution Threat Analysis

    • Table Threat of New Entrants Analysis

    • Table Competitive Rivalry Analysis

    • Figure Global Ischemic Heart Disease (IHD)Drugs Consumption by Country (2017-2022)

    • Figure United States Ischemic Heart Disease (IHD)Drugs Consumption and Growth Rate (2017-2022)

    • Table Europe Ischemic Heart Disease (IHD)Drugs Consumption and Growth Rate (2017-2022)

    • Figure China Ischemic Heart Disease (IHD)Drugs Consumption and Growth Rate (2017-2022)

    • Figure Japan Ischemic Heart Disease (IHD)Drugs Consumption and Growth Rate (2017-2022)

    • Figure India Ischemic Heart Disease (IHD)Drugs Consumption and Growth Rate (2017-2022)

    • Figure South Korea Ischemic Heart Disease (IHD)Drugs Consumption and Growth Rate (2017-2022)

    • Figure Global Ischemic Heart Disease (IHD)Drugs Consumption Forecast by Country (2022-2028)

    • Figure United States Ischemic Heart Disease (IHD)Drugs Consumption Forecast and Growth Rate (2022-2028)

    • Table Europe Ischemic Heart Disease (IHD)Drugs Consumption Forecast and Growth Rate (2022-2028)

    • Figure China Ischemic Heart Disease (IHD)Drugs Consumption Forecast and Growth Rate (2022-2028)

    • Figure Japan Ischemic Heart Disease (IHD)Drugs Consumption Forecast and Growth Rate (2022-2028)

    • Figure India Ischemic Heart Disease (IHD)Drugs Consumption Forecast and Growth Rate (2022-2028)

    • Figure South Korea Ischemic Heart Disease (IHD)Drugs Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Anti-dyslipidemic Drugs Consumption and Growth Rate (2017-2022)

    • Figure Global Calcium Channel Blockers Consumption and Growth Rate (2017-2022)

    • Figure Global Beta-blockers Consumption and Growth Rate (2017-2022)

    • Figure Global ACE Inhibitors Consumption and Growth Rate (2017-2022)

    • Figure Global ARBs Consumption and Growth Rate (2017-2022)

    • Figure Global Vasodilators Consumption and Growth Rate (2017-2022)

    • Figure Global Antithrombotic Agents Consumption and Growth Rate (2017-2022)

    • Figure Global Stable Angina Consumption and Growth Rate (2017-2022)

    • Figure Global Unstable Angina Consumption and Growth Rate (2017-2022)

    • Figure Global Prinzmetal's Angina Consumption and Growth Rate (2017-2022)

    • Figure Global STEMI Consumption and Growth Rate (2017-2022)

    • Figure Global NSTEMI Consumption and Growth Rate (2017-2022)

    • Figure Global Anti-dyslipidemic Drugs Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Calcium Channel Blockers Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Beta-blockers Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global ACE Inhibitors Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global ARBs Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Vasodilators Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Antithrombotic Agents Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Stable Angina Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Unstable Angina Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Prinzmetal's Angina Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global STEMI Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global NSTEMI Consumption Forecast and Growth Rate (2022-2028)

    • Table Global Ischemic Heart Disease (IHD)Drugs Import by Region (Top 5 Countries) (2017-2028)

    • Table Global Ischemic Heart Disease (IHD)Drugs Export by Region (Top 5 Countries) (2017-2028)

    • Table AstraZeneca (Foundation Year, Company Profile and etc.)

    • Table AstraZeneca Ischemic Heart Disease (IHD)Drugs Sales, Price, Value and Gross Profit (2017-2022)

    • Table AstraZeneca Ischemic Heart Disease (IHD)Drugs Product and Service

    • Table Sanofi (Foundation Year, Company Profile and etc.)

    • Table Sanofi Ischemic Heart Disease (IHD)Drugs Sales, Price, Value and Gross Profit (2017-2022)

    • Table Sanofi Ischemic Heart Disease (IHD)Drugs Product and Service

    • Table Novartis (Foundation Year, Company Profile and etc.)

    • Table Novartis Ischemic Heart Disease (IHD)Drugs Sales, Price, Value and Gross Profit (2017-2022)

    • Table Novartis Ischemic Heart Disease (IHD)Drugs Product and Service

    • Table Bayer (Foundation Year, Company Profile and etc.)

    • Table Bayer Ischemic Heart Disease (IHD)Drugs Sales, Price, Value and Gross Profit (2017-2022)

    • Table Bayer Ischemic Heart Disease (IHD)Drugs Product and Service

    • Table Eli Lilly (Foundation Year, Company Profile and etc.)

    • Table Eli Lilly Ischemic Heart Disease (IHD)Drugs Sales, Price, Value and Gross Profit (2017-2022)

    • Table Eli Lilly Ischemic Heart Disease (IHD)Drugs Product and Service

    • Table Pfizer (Foundation Year, Company Profile and etc.)

    • Table Pfizer Ischemic Heart Disease (IHD)Drugs Sales, Price, Value and Gross Profit (2017-2022)

    • Table Pfizer Ischemic Heart Disease (IHD)Drugs Product and Service


Report Version Choose

Report

BUY NOW

Our Customers

Beyond grateful for the confidence and support from all partners and customers.A win-win situation is our ultimate pursuit.

Beyond Consulting, Future is Feasible

We provide more professional and intelligent market reports to complement your business decisions.

CONTACT US